Enanta Pharmaceuticals’ Partner AbbVie Receives European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus
The European Commission approved AbbVie's MAVIRET (glecaprevir/pibrentasvir) for the treatment of acute Hepatitis C Virus infection, making it the only pan-genotypic treatment in the EU approved for both acute and chronic HCV. Glecaprevir, one of the drug's components, was discovered by Enanta Pharmaceuticals; this label expansion is expected to increase the treatable patient population and support the company's royalty revenues.
Key figures
- Study patients
- 286
- Svr12 rate itt
- 96.2%
- Study locations
- 70
- Svr12 rate modified itt vf
- 100%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.